DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 208743
NDA 208743 describes TYMLOS, which is a drug marketed by Radius Health Inc and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the TYMLOS profile page.
The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this compound. Additional details are available on the abaloparatide profile page.
The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this compound. Additional details are available on the abaloparatide profile page.
Summary for 208743
| Tradename: | TYMLOS |
| Applicant: | Radius Health Inc |
| Ingredient: | abaloparatide |
| Patents: | 3 |
Generic Entry Opportunity Date for 208743
Generic Entry Date for 208743*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 208743
| Ingredient-type | Parathyroid Hormone-Related Protein Analogs/Derivatives |
Suppliers and Packaging for NDA: 208743
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743 | NDA | Radius Health, Inc. | 70539-001 | 70539-001-02 | 1 CARTRIDGE in 1 BOX, UNIT-DOSE (70539-001-02) > 1.56 mL in 1 CARTRIDGE (70539-001-01) |
| TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743 | NDA | Radius Health, Inc. | 70539-001 | 70539-001-98 | 1 CARTRIDGE in 1 BOX, UNIT-DOSE (70539-001-98) > 1.56 mL in 1 CARTRIDGE (70539-001-99) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 3.12MG/1.56ML (2MG/ML) | ||||
| Approval Date: | Apr 28, 2017 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Apr 28, 2022 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Mar 26, 2028 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE. | ||||||||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Nov 8, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
